76 results
Page 2 of 4
8-K
EX-99.1
oeg7l 6lpx
7 Aug 18
BioCryst Reports Second Quarter 2018 Financial Results
7:31am
425
1v45rti ud
21 Jun 18
Business combination disclosure
6:06am
425
m7ql2ig vbqz0ap
21 Jun 18
Business combination disclosure
12:00am
425
jlx3yv1dof
7 Jun 18
Business combination disclosure
8:17am
425
7hiogld uiuw
7 Jun 18
Business combination disclosure
8:15am
8-K
z5h8bhz34momzlyq9nx1
24 May 18
BioCryst's BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema
4:00pm
8-K
EX-99.1
at4qy8x
24 May 18
BioCryst's BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema
4:00pm
425
evfhsi9 9oakljh4pei
22 Jan 18
Business combination disclosure
12:00am
8-K
EX-99.1
nv6rdv
7 Dec 12
Biocryst Pharmaceuticals Announces Focused Corporate Strategy
12:00am
8-K
EX-99.1
8itmivfox5adtrkm0g
30 Nov 12
Termination of a Material Definitive Agreement
12:00am
8-K
EX-99.1
wnssa4sl21f9wyr
8 Nov 12
Biocryst Announces Outcome from the Peramivir Phase 3 Interim Analysis
12:00am
8-K
EX-99.1
8i37iwix6hmdzllkit8
8 Nov 12
Biocryst Provides Corporate Update and Reports Third Quarter
12:00am
425
EX-99.1
kw0su 100a
8 Nov 12
Business combination disclosure
12:00am